Pharmacology and Toxicology

Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy

1. Leying Chen
2. Qing You
3. Min Liu
4. Shuaihu Li
5. Zhaoyu Wu
6. Jiajun Hu
7. Yurui Ma
8. Liangyong Xia
9. Ying Zhou
10. Nan Xu
11. Shiyi Zhang

• Curated by eLife

  Evaluation Summary:

  This paper will be of interest to oncologists and dermatologists and has high clinical relevance. It reveals a novel mechanism of EGFR inhibitor-induced rash which be may closely related to atrophy of dermal white adipose tissue (dWAT). A series of experimental manipulations dissect the mechanism with a murine model, supporting the major claims of the paper.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. The reviewers remained anonymous to the authors.)

Reviewed by eLife

Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor

1. Chunlong Ma
2. Yanmei Hu
3. Yuyin Wang
4. Juliana Choza
5. Jun Wang

Reviewed by ScreenIT

Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo

1. Otávio Augusto Chaves
2. Carolina Q. Sacramento
3. André C. Ferreira
4. Mayara Mattos
5. Natalia Fintelman-Rodrigues
6. Jairo R. Temerozo
7. Leonardo Vazquez
8. Douglas Pereira Pinto
9. Gabriel P. E. da Silveira
10. Laís Bastos da Fonseca
11. Heliana Martins Pereira
12. Aluana Santana Carlos
13. Joana C. d’Avila
14. João P. B. Viola
15. Robson Q. Monteiro
16. Patrícia T. Bozza
17. Hugo Caire Castro-Faria-Neto
18. Thiago Moreno L. Souza

Reviewed by ScreenIT

Hypertonic saline and aprotinin based blockage of SARS-CoV-2 specific furin site cleavage by inhibition of nasal protease activity

1. Clarissa Li
2. Adam W. Li

Reviewed by ScreenIT

Dual Effects of Nanoviricides Platform Technology Based NV-CoV-2 Biomimetic Polymer Against COVID-19

1. Anil Diwan
2. Ashok Chakraborty
3. Vijetha Chiniga
4. Vinod Arora
5. Preetam Holkar
6. Yogesh Thakur
7. Jay Tatake
8. Randall Barton
9. Neelam Holkar
10. Bethany Pond

Reviewed by ScreenIT

Nanoviricide’s platform technology based NV-CoV-2 polymer increases the half-life of Remdesivir in vivo

1. Ashok Chakraborty
2. Anil Diwan
3. Vinod Arora
4. Yogesh Thakur
5. Vijetha Chiniga
6. Jay Tatake
7. Preetam Holkar
8. Neelam Holkar
9. Bethany Pond

Reviewed by ScreenIT

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors

1. Chunlong Ma
2. Jun Wang

Reviewed by ScreenIT

Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell

1. Yanmei Hu
2. Hyunil Jo
3. William F. DeGrado
4. Jun Wang

Reviewed by ScreenIT

Novel pectin from crude polysaccharide of Syzygium aromaticum against SARS-CoV-2 activities by targeting 3CLpro

1. Can Jin
2. Bo Feng
3. Rongjuan Pei
4. Yaqi Ding
5. Meixia Li
6. Xia Chen
7. Zhenyun Du
8. Yangxiao Ding
9. Chunfan Huang
10. Bo Zhang
11. Xinwen Chen
12. Yi Zang
13. Jia Li
14. Kan Ding

Reviewed by ScreenIT

Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants

1. Daniela Iaconis
2. Licia Bordi
3. Giulia Matusali
4. Carmine Talarico
5. Candida Manelfi
6. Maria Candida Cesta
7. Mara Zippoli
8. Francesca Caccuri
9. Antonella Bugatti
10. Alberto Zani
11. Federica Filippini
12. Laura Scorzolini
13. Marco Gobbi
14. Marten Beeg
15. Arianna Piotti
16. Monica Montopoli
17. Veronica Cocetta
18. Silvia Bressan
19. Enrico M. Bucci
20. Arnaldo Caruso
21. Emanuele Nicastri
22. Marcello Allegretti
23. Andrea R. Beccari

Reviewed by ScreenIT